to its investors that increases over time. The REIT has certainly succeeded in that mission over the years. It has raised its ...

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Walmart's results showcase the nuances of purchasing decisions. Often, consumers don't eliminate a purchase, but shift the ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

AMD's growth has been accelerating, and its chips have been attracting the attention of leading artificial intelligence (AI) ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Schulman has wasted little time in making a big shakeup, with the company recently announcing that it will be laying off ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

A lot can change in five years. Take Vertex Pharmaceuticals ( VRTX +0.57%), for example. In late 2020, the big biotech ...